Articles related to GUIDELINES/RECOMMENDATIONS

Recent evidence suggests that shorter preoperative fasting, as recommended by major anesthesiology societies, can enhance patient comfort without increasing surgical risks.

The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.

The commentary presents a compelling analysis of the paradoxical views on long-term benzodiazepine treatment, highlighting the need for evidence-based practice guidelines. It underscores the importance of considering both the challenges of withdrawal and the potential efficacy of long-term use in well-characterized DSM anxiety disorders.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.

The introduction of these new guidelines marks a significant advancement in our understanding and determination of brain death. An emphasis on standardization and accuracy, these guidelines could change how we approach this critical aspect of medical practice.

Stay informed about the increasing prevalence of xylazine in illegally manufactured fentanyl. Learn about its impact on patient care and discover strategies for effective treatment and harm reduction.